OncoSil Medical Gains TGA Nod for Class III Pancreatic Cancer Device
OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.
- TGA approval for OncoSil™ device in pancreatic cancer
- First Class III device targeting pancreatic tumours in Australia
- 4,353 new pancreatic cancer cases annually in Australia
- New Sydney manufacturing facility nearing completion
- Approval supports global commercialisation and clinician adoption
TGA Approval Breaks New Ground in Pancreatic Cancer Treatment
OncoSil Medical (ASX:OSL) has achieved a significant regulatory milestone with the Therapeutic Goods Administration (TGA) granting approval for its OncoSil™ device to treat unresectable locally advanced pancreatic cancer (LAPC) in Australia. This marks the first and only Class III medical device in the country designed to deliver targeted radiotherapy directly to pancreatic tumours, a notoriously difficult cancer to treat with limited options and poor survival rates.
Each year, around 4,353 Australians are diagnosed with pancreatic cancer, the eighth most common cancer nationally. The TGA approval not only opens the door for OncoSil to commercialise its device domestically but also bolsters clinician confidence and patient access to this novel treatment, which is used alongside gemcitabine-based chemotherapy.
Clinical Validation and Market Momentum
OncoSil’s CEO Nigel Lange emphasised the importance of the approval, highlighting the rigorous Class III regulatory review the device underwent. He noted that this milestone validates the company’s clinical and regulatory strategy and strengthens its global commercial ambitions. The approval is expected to accelerate clinical adoption in Australia and support future regulatory submissions internationally.
Backing this optimism is a growing body of clinical evidence. The company’s recent interim data from the OSPREY Registry demonstrated strong safety and promising survival outcomes, including a median overall survival exceeding 20 months and a notable proportion of patients downstaged to surgery with high R0 resection rates. These results have been pivotal in building clinician engagement and confidence in the OncoSil™ device’s potential benefits for LAPC patients encouraging OSPREY Registry interim results.
Manufacturing Expansion to Support Commercial Scale
Complementing the regulatory win, OncoSil is nearing completion of a new manufacturing facility in Macquarie Park, Sydney, developed in partnership with Cyclotek. This facility is designed to underpin both domestic and international supply chains as the company scales commercial operations. The timing aligns with recent operational improvements, including a 60% year-on-year increase in dose sales and expansion of treatment centres, positioning OncoSil for growth in a competitive oncology market dose sales surge 60 percent.
Expert Endorsement Highlights Clinical Value
Professor Nam Nguyen, Head of Endoscopy at the Royal Adelaide Hospital, underscored the significance of the TGA approval, calling it an important advancement for Australian clinicians and patients. He pointed to the device’s ability to help patients become eligible for surgery; a key factor in improving long-term outcomes; and its potential to deliver survival benefits when integrated into multidisciplinary treatment pathways. This expert endorsement adds weight to OncoSil’s case for broader adoption in clinical practice.
Bottom Line?
OncoSil’s TGA approval sets the stage for domestic commercialisation and strengthens its global growth prospects, but market uptake and reimbursement pathways will be critical next hurdles.
Questions in the middle?
- How quickly will Australian clinicians adopt OncoSil™ following TGA approval?
- What reimbursement strategies will OncoSil pursue to ensure patient access?
- Can the new Sydney manufacturing facility meet anticipated global demand?
